Compare BridgeBio Pharma Inc (BBIO) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs ABRDN Physical Gold Shares ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while ABRDN Physical Gold Shares ETF trades at $41.86. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | SGOL | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $90.17 | $51.41 |
52-Week Low | $47.29 | $31.61 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
SGOL, a US-listed gold ETF, trades at $41.35, up 2.22% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights gold's rebound potential, driven by central bank buying and dovish Fed expectations. The stock shows strong support at $41 and resistance at $42, with institutional sentiment leaning positive amid macroeconomic support for precious metals.
Outlook remains cautiously optimistic as gold benefits from lower real yields and geopolitical factors, though overbought conditions near-term pose a risk. Investment appeal hinges on sustained macroeconomic trends, while volatility from dollar movements and profit-taking presents challenges for short-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
